plx51107
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02683395)
Timeline
Indications
Mechanism of action
- Bromodomain testis-specific proteinINHIBITOR
BRDT inhibitor
- Bromodomain-containing protein 2INHIBITOR
BRD2 inhibitor
- Bromodomain-containing protein 3INHIBITOR
BRD3 inhibitor
- BRD4/HDAC1INHIBITOR
BRD4/HDAC1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- plx51107
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07168902 | Phase 2 | Oct 24, 2025 | Bausch & Lomb |
| NCT04910152 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2021 | Ohio State University, Plexxikon |
| NCT04022785 | Phase 1 | Jul 31, 2019 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT02683395 | Phase 1 | Mar 1, 2016 | Plexxikon |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Plexxikon | For profit | 2 | 1 | 2 | 2016 |
| Bausch & Lomb | For profit | 1 | 1 | 1 | 2025 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2019 |
5 organizations
Page 1 / 1